Literature DB >> 8924237

Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine.

M G Goulden, N Cammack, P L Hopewell, C R Penn, J M Cameron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8924237     DOI： 10.1097/00002030-199601000-00015

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

2.  A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.

Authors:  S D Kemp; C Shi; S Bloor; P R Harrigan; J W Mellors; B A Larder
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 3.  Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.

Authors:  C M Perry; D Faulds
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

5.  Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Authors:  X J Zhou; L B Sheiner; R T D'Aquila; M D Hughes; M S Hirsch; M A Fischl; V A Johnson; M Myers; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.